Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines

Table 1 Eag1 immunoreactivity in the colorectal cancers

Stage	Eag1 expression1			Positive cases
	Negative	Weak	Strong	n (%)
A	3	2	2	4/7 (57.1)
B	13	14	12	26/39 (66.7)
C	2	5	9	14/16 (87.5)
D	0	5	9	14/14 (100)
Total	18	26	32	58/76 (76.3)

¹Intensity of expression was interpreted as negative, weakly positive, and strongly positive, P < 0.05.

Table 2 Clinico-pathological features and Eag1 protein expression

Clinico-pathologicalfeatures	Number of tumorn (%)	Positive Eag1expression n (%)	χ2 value
Sex			0.70
Male	44 (57.9)	32(72.2)
Female	32 (42.1)	26(81.3)
Age (yr)			0.002
< 60	51 (67.1)	39 (76.5)
≥ 60	25 (32.9)	19 (76.0)
Location			4.52
Recta	28 (36.8)	22 (78.6)
Left colon	21 (27.6)	16 (76.2)
Transverse colon	9 (11.8)	6 (66.7)
Right colon	18 (23.7)	14 (77.8)
Differentiation			2.09
High	18 (23.7)	12 (66.7)
Moderate	22 (28.9)	16 (72.7)
Low	29 (38.2)	24 (82.8)
Undifferentiated	7 (9.2)	6 (85.7)
Size			6.41a
< 5 cm	48 (63.2)	32 (66.7)
≥ 5 cm	28 (36.8)	26 (92.9)
Lymphatic node metastasis			5.14a
N0	46 (60.5)	31 (67.4)
N1	30 (39.5)	27 (90.0)
Other organs metastasis			4.59a
M0	62 (81.6)	44 (71.0)
M1	14 (18.4)	14 (100)
Dukes’ stage			8.89a
A	7 (9.2)	4 (57.1)
B	39 (51.3)	26 (66.7)
C	16 (21.1)	14 (87.5)
D	14 (18.4)	14 (100)

^aP < 0.05.